COMPASS Pathways plc

NasdaqGS:CMPS Stock Report

Market Cap: US$283.9m

COMPASS Pathways Future Growth

Future criteria checks 0/6

COMPASS Pathways is forecast to grow earnings and revenue by 25.8% and 70.2% per annum respectively. EPS is expected to grow by 29.6% per annum. Return on equity is forecast to be -54.8% in 3 years.

Key information

25.8%

Earnings growth rate

29.6%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate70.2%
Future return on equity-54.8%
Analyst coverage

Good

Last updated08 Nov 2024

Recent future growth updates

Recent updates

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Nov 01

Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision

Aug 19

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Jul 08

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

May 23

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Feb 08

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Dec 06
Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Booker again pushes for easier access to psychedelics for terminally ill patients

Oct 19

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

COMPASS Pathways And The Trillion Dollar Opportunity

Aug 11

COMPASS Pathways ADS Q2 2022 Earnings Preview

Aug 03

COMPASS Pathways names new CEO

Jul 19

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

Jun 30

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Apr 28
We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

Checking In On Compass Pathways

Mar 02

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Dec 29
We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Compass Pathways: Psychedelics For Mental Health

Nov 23

Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy

Sep 17

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

Sep 15
COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

Compass Pathways: Huge Growth Potential, But I'm Cautious

Jun 04

COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

May 25
COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans

COMPASS Pathways raises $144M capital via equity offering

Apr 30

COMPASS Pathways launches public offering

Apr 27

We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate

Feb 08
We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

Jan 01

Compass Pathways: Risky And Overvalued

Dec 18

What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Dec 18
What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Earnings and Revenue Growth Forecasts

NasdaqGS:CMPS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276-134-128-1195
12/31/2026N/A-154-141-1346
12/31/2025N/A-153-136-1347
12/31/2024N/A-157-116-1158
9/30/2024N/A-144-105-105N/A
6/30/2024N/A-139-100-100N/A
3/31/2024N/A-129-91-90N/A
12/31/2023N/A-118-97-97N/A
9/30/2023N/A-117-115-115N/A
6/30/2023N/A-102-117-117N/A
3/31/2023N/A-95-111-110N/A
12/31/2022N/A-92-106-105N/A
9/30/2022N/A-86-83-83N/A
6/30/2022N/A-84-78-77N/A
3/31/2022N/A-80-77-77N/A
12/31/2021N/A-72-68-68N/A
9/30/2021N/A-65-62-62N/A
6/30/2021N/A-66-62-62N/A
3/31/2021N/A-64-51-51N/A
12/31/2020N/A-60-42-41N/A
9/30/2020N/A-49-31-31N/A
6/30/2020N/A-38-22-22N/A
3/31/2020N/A-25-19-19N/A
12/31/2019N/A-20-18-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMPS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMPS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMPS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMPS is forecast to have no revenue next year.

High Growth Revenue: CMPS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CMPS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 01:22
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

COMPASS Pathways plc is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.